Related Experiment Video
Updated: Jun 22, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
1Clinical Research Fellow, Imperial College London, Division of Medicine, Ground Floor, Clinical Trials, Winston Churchill Wing, London W21PG, London, UK. l.garvey@imperial.ac.uk
Expert Opinion on Investigational Drugs
|June 25, 2009
Summary
Rilpivirine, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), shows high antiviral activity and similar virological suppression to efavirenz in HIV-1 treatment-naive individuals. It offers a better safety profile with less central nervous system disturbance.
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- Combination antiretroviral therapy has improved HIV-1 prognosis.
- Efavirenz is a recommended first-line NNRTI but has limitations.
- Next-generation NNRTIs are under development to overcome efavirenz's drawbacks.
Purpose of the Study:
- To review the development and clinical trial status of rilpivirine.
- To evaluate rilpivirine's efficacy, safety, and pharmacokinetic profile.
- To compare rilpivirine with efavirenz in treatment-naive HIV-1 infected individuals.
Main Methods:
- Review of rilpivirine's discovery and progression through Phase I, II, and III clinical trials.
- Analysis of in vitro antiviral activity, including against NNRTI-resistant isolates.
- Assessment of pharmacokinetic data, food and drug interactions, and safety profiles.
Main Results:
- Rilpivirine demonstrated high in vitro antiviral activity.
- Phase III trials show similar virological suppression rates to efavirenz at 96 weeks.
- Rilpivirine exhibits a favorable safety profile with reduced CNS toxicity compared to efavirenz.
Conclusions:
- Rilpivirine is a promising NNRTI for HIV-1 treatment.
- It offers comparable efficacy to efavirenz with an improved safety profile.
- Potential drug interactions, particularly with acid suppressants, require careful management.
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:29Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...